3SMO.PA up 9.93% to €632.53 on EURONEXT close 29 Jan 2026: short ETP outlook
GraniteShares 3x Short Moderna (3SMO.PA stock) closed on EURONEXT at €632.53, up 9.93% on 29 Jan 2026 as markets ended the session. The move made 3SMO.PA one of the larger percentage gainers on the exchange at close, trading between €576.00 and €632.53 intraday. Volume was light at 3 shares versus an average of 29, but the price action pushed the ETP nearer its 50-day average of €442.02, highlighting sharp short-term volatility in this leveraged product. This piece breaks down drivers, technicals, Meyka AI grading and scenario forecasts for traders and investors on EURONEXT in EUR.
3SMO.PA stock: intraday price action and volume
3SMO.PA stock closed at €632.53, a +9.93% change from the previous close of €575.37. The session high was €632.53 and the low was €576.00, showing a tight intraday trading range that finished at the top. Trading volume was 3 shares, below the 29 average volume, which indicates the percentage move occurred on limited liquidity and may not reflect broad market conviction.
One clear metric: the 50-day average price is €442.02 and the 200-day average is €183.21, signifying a recent strength in price despite low absolute turnover. For EURONEXT traders, the combination of sharp percentage moves and thin volume underlines risk for market orders and wider spreads.
What drove today’s move: news, sector and Moderna link
GraniteShares 3x Short Moderna is a leveraged daily ETP designed to deliver three times the inverse performance of MRNA, so moves in Moderna shares or sector commentary can drive 3SMO.PA stock sharply. Today’s rise likely tracks short-term swings in Moderna-related headlines and biotech sector volatility rather than new fund fundamentals. The ETP reflects daily rebalancing of exposure to MRNA, not company-level earnings.
Healthcare sector readings show modest pressure overall, while the broader Financial Services sector on EURONEXT is steady. Traders should monitor direct Moderna (MRNA) news and biotech indices for follow-through; leveraged ETPs magnify those moves inside a single trading day.
Technical snapshot and Meyka AI grade for 3SMO.PA stock
Technicals show mixed momentum: RSI 37.07 sits near oversold thresholds, MACD -33.78 vs signal -9.27 indicates bearish momentum, and ATR 73.97 flags high volatility. Bollinger bands run €212.09–€659.25, with price currently near the upper band at close. On balance, indicators point to a volatile, short-term trade setup rather than a stable trend.
Meyka AI rates 3SMO.PA with a score out of 100: 62.63 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs, not guaranteed results and not financial advice.
Valuation, structure and key risks for 3SMO.PA stock
3SMO.PA is an ETP; traditional valuation ratios like P/E are not applicable, and reported PE/EPS are null. Market cap stands at €11,407,046.00 with 18,034 shares outstanding. The product’s design to deliver daily -3x exposure to Moderna introduces path dependency and decay risk for multi-day holders.
Primary risks: leveraged compounding over multiple sessions, low liquidity on EURONEXT that can widen spreads, and correlation risk if MRNA does not move cleanly with biotech indexes. Investors should treat 3SMO.PA stock as a short-term trading tool, not a buy-and-hold instrument.
Trading strategy and outlook: short-term setups and forecasts
For traders, the immediate setup is intraday mean-reversion or momentum continuation depending on MRNA headlines. Use limit orders and narrow position sizing given the thin volume and high ATR €73.97. Watch key technical levels: support near €576.00 and initial resistance at the session high €632.53.
Meyka AI’s forecast model projects scenario targets to contextualise risk. In a base case the model sees €540.00 (implied downside -14.63% from current price), a bear case at €260.00 (implied downside -58.87%), and a bull case at €810.00 (implied upside +28.07%). Forecasts are model-based projections and not guarantees.
Final Thoughts
3SMO.PA stock finished the EURONEXT session on 29 Jan 2026 at €632.53, a +9.93% intraday move driven by short-term swings in Moderna-related flows and the product’s leveraged structure. The ETP’s thin trading volume (3 shares) increases execution risk and can amplify price swings. Technicals signal high volatility with RSI 37.07 and ATR €73.97, pointing to trading opportunity but elevated risk. Meyka AI’s forecast model projects a base target of €540.00 (implied -14.63%), a bear target €260.00 (-58.87%), and a bull target €810.00 (+28.07%) versus the current €632.53. Remember, leveraged daily ETPs are designed for short-term use; monitor MRNA headlines and use tight risk controls. Meyka AI provides this as an AI-powered market analysis platform insight; forecasts are model-based and not guarantees.
FAQs
What is 3SMO.PA stock and how does it work?
3SMO.PA stock is GraniteShares 3x Short Moderna, a leveraged daily ETP on EURONEXT that seeks three times the inverse of Moderna (MRNA) returns. It targets daily moves and is unsuitable for long-term buy-and-hold due to compounding and rebalancing effects.
Why did 3SMO.PA stock move sharply today?
The €632.53 close and +9.93% change on 29 Jan 2026 reflect short-term swings in Moderna-related flows and leveraged rebalancing. Low volume (3 shares) means the move occurred on limited liquidity, which can exaggerate percentage changes.
What is Meyka AI’s grade and forecast for 3SMO.PA stock?
Meyka AI rates 3SMO.PA 62.63/100 (Grade: B, Suggestion: HOLD). The model projects a base target €540.00, bear €260.00, and bull €810.00. Forecasts are model projections and not guarantees.
Is 3SMO.PA stock suitable for long-term investors?
No. 3SMO.PA is a daily leveraged inverse ETP with path dependency and decay risk. It is designed for short-term tactical trades, not long-term buy-and-hold strategies.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
